<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6356912</article-id><article-id pub-id-type="doi">10.3390/md17010043</article-id><article-id pub-id-type="publisher-id">marinedrugs-17-00043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Synthesis and Evaluation of a Chitosan Oligosaccharide-Streptomycin Conjugate against <italic>Pseudomonas aeruginosa</italic> Biofilms</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9952-6093</contrib-id><name><surname>Li</surname><given-names>Ruilian</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-17-00043">1</xref><xref ref-type="aff" rid="af2-marinedrugs-17-00043">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Xianghua</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00043">3</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Jinhua</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-17-00043">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiafei</given-names></name><xref ref-type="aff" rid="af3-marinedrugs-17-00043">3</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Gong</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-17-00043">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4707-036X</contrib-id><name><surname>Wang</surname><given-names>Zhuo A.</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-17-00043">2</xref><xref rid="c1-marinedrugs-17-00043" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Yuguang</given-names></name><xref ref-type="aff" rid="af2-marinedrugs-17-00043">2</xref><xref rid="c1-marinedrugs-17-00043" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-marinedrugs-17-00043"><label>1</label>University of Chinese Academy of Sciences, Beijing 100049, China; <email>rlli@ipe.ac.cn</email></aff><aff id="af2-marinedrugs-17-00043"><label>2</label>Key Laboratory of Biopharmaceutical Production &#x00026; Formulation Engineering, PLA and State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; <email>jhwei@ipe.ac.cn</email> (J.W.); <email>gcheng@ipe.ac.cn</email> (G.C.)</aff><aff id="af3-marinedrugs-17-00043"><label>3</label>College of Life Science, Sichuan Normal University, Chengdu 610101, China; <email>lemonlyty@sohu.com</email> (X.Y.); <email>feifei_2016@126.com</email> (X.Z.)</aff><author-notes><corresp id="c1-marinedrugs-17-00043"><label>*</label>Correspondence: <email>wangzhuo@ipe.ac.cn</email> (Z.A.W.); <email>ygdu@ipe.ac.cn</email> (Y.D.); Tel./Fax: +86-10-8254-5070 (Z.A.W. &#x00026; Y.D.)</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>43</elocation-id><history><date date-type="received"><day>28</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>07</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Microbial biofilms are considerably more resistant to antibiotics than planktonic cells. It has been reported that chitosan coupling with the aminoglycoside antibiotic streptomycin dramatically disrupted biofilms of several Gram-positive bacteria. This finding suggested the application of the covalent conjugate of antimicrobial natural polysaccharides and antibiotics on anti-infection therapy. However, the underlying molecular mechanism of the chitosan-streptomycin conjugate (CS-Strep) remains unclear and the poor water-solubility of the conjugate might restrict its applications for anti-infection therapy. In this study, we conjugated streptomycin with water-soluble chitosan oligosaccharides (COS). Unlike CS-Strep, the COS-streptomycin conjugate (COS-Strep) barely affected biofilms of tested Gram-positive bacteria. However, COS-Strep efficiently eradicated established biofilms of the Gram-negative pathogen <italic>Pseudomonas aeruginosa</italic>. This activity of COS-Strep was influenced by the degree of polymerization of chitosan oligosaccharide. The increased susceptibility of <italic>P. aeruginosa</italic> biofilms to antibiotics after conjugating might be related to the following: Suppression of the activation of MexX-MexY drug efflux pump system induced by streptomycin treatment; and down-regulation of the biosynthesis of biofilm exopolysaccharides. Thus, this work indicated that covalently linking antibiotics to chitosan oligosaccharides was a possible approach for the development of antimicrobial drugs against biofilm-related infections.</p></abstract><kwd-group><kwd>chitosan oligosaccharides</kwd><kwd>streptomycin</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd><kwd>biofilms</kwd><kwd>conjugation</kwd></kwd-group></article-meta></front><body><sec id="sec1-marinedrugs-17-00043"><title>1. Introduction</title><p>Biofilms are a form of existence of microorganisms encapsulated in an extracellular matrix that holds cells together and forms a three-dimensional structure against environmental challenges [<xref rid="B1-marinedrugs-17-00043" ref-type="bibr">1</xref>]. Recent studies indicated the antimicrobial resistance in bacteria was closely related to the formation of biofilms, which is associated with about 75% of human bacterial infections [<xref rid="B2-marinedrugs-17-00043" ref-type="bibr">2</xref>,<xref rid="B3-marinedrugs-17-00043" ref-type="bibr">3</xref>,<xref rid="B4-marinedrugs-17-00043" ref-type="bibr">4</xref>,<xref rid="B5-marinedrugs-17-00043" ref-type="bibr">5</xref>]. The drug-resistance of bacteria in biofilms raised 10&#x02013;1000 times compared to their planktonic counterparts [<xref rid="B6-marinedrugs-17-00043" ref-type="bibr">6</xref>,<xref rid="B7-marinedrugs-17-00043" ref-type="bibr">7</xref>,<xref rid="B8-marinedrugs-17-00043" ref-type="bibr">8</xref>]. Several factors have been attributed to the resistance, including hampered penetration of antimicrobials through the biofilm matrix, upregulation of the drug efflux pump system, etc. [<xref rid="B9-marinedrugs-17-00043" ref-type="bibr">9</xref>,<xref rid="B10-marinedrugs-17-00043" ref-type="bibr">10</xref>]. There are limited drugs specifically targeting the biofilms of bacteria. The development of biofilm-specific drugs to treat biofilm-related infections is urged.</p><p>Chitosan coupled with streptomycin (CS-Strep) could efficiently disrupted the pre-formed bacterial biofilms. However, the anti-biofilm specificity of CS-Strep was likely restricted to Gram-positive organisms such as <italic>Staphylococcus aureus</italic>, <italic>Listeria monocytogenes</italic>, <italic>Enterococcus faecalis</italic>, but not Gram-negative bacteria <italic>Pseudomonas aeruginosa</italic> [<xref rid="B11-marinedrugs-17-00043" ref-type="bibr">11</xref>,<xref rid="B12-marinedrugs-17-00043" ref-type="bibr">12</xref>]. These findings suggested an innovative strategy to combat biofilm-related infections by conjugating antibiotics with natural polysaccharides. However, the mechanism behind this intriguing activity is still unclear. The low water solubility and high viscosity of chitosan and CS-Strep might restrict their applications on anti-biofilm therapies. </p><p>Chitosan oligosaccharides (COS), composed of &#x003b2;-(1-4)-linked D-glucosamine and <italic>N</italic>-acetyl-D-glucosamine with the degree of polymerization (DP) 2&#x02013;10, were prepared from degradation of chitosan. Compared to chitosan, COS have a much lower average molecular weight (MW) and better water-solubility [<xref rid="B13-marinedrugs-17-00043" ref-type="bibr">13</xref>]. COS also possess versatile biological activities, such as antimicrobial, antioxidant, anticancer, and immune-stimulant effects [<xref rid="B14-marinedrugs-17-00043" ref-type="bibr">14</xref>]. In this study, we coupled streptomycin with COS. The anti-biofilm activities of the COS-streptomycin conjugate (COS-Strep) against bacterial biofilms were evaluated. The structure and function relationships of the anti-biofilm activities were preliminarily explored. </p></sec><sec id="sec2-marinedrugs-17-00043"><title>2. Materials and Methods</title><sec id="sec2dot1-marinedrugs-17-00043"><title>2.1. Reagents and Bacteria Strains</title><p>COS (DP 2~8, average MW: 835) and COS2 (DP 2~20, average MW: 1419) were purchased from GlycoBio (GlycoBio, Dalian, China). The average MW and DP of COS was determined by HPLC and LC-MS [<xref rid="B15-marinedrugs-17-00043" ref-type="bibr">15</xref>] (<xref ref-type="app" rid="app1-marinedrugs-17-00043">Figure S1</xref>). Chitosan with MW of 50&#x02013;190 kD was purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Streptomycin (Strep) was purchased from Solarbio (Solarbio, Beijing, China). The <italic>P. aeruginosa</italic> (PAO1) strain used in the experiment was generously granted by Prof. Ma Lvyan. The <italic>S. aureus</italic> strain (CGMCC1.2910) was purchased from China General Microbiological Culture Collection Center (CGMCC). <italic>L. monocytogenes</italic> (CVCC1597) was purchased from China Veterinary Culture Collection Center (CVCC). <italic>P. aeruginosa</italic> and <italic>L. monocytogenes</italic> were cultured with LB medium at 28 or 37 &#x000b0;C respectively. <italic>S. aureus</italic> was cultured with TSB medium at 37 &#x000b0;C. </p></sec><sec id="sec2dot2-marinedrugs-17-00043"><title>2.2. Synthesis of Chitosan Oligosaccharide&#x02013;Streptomycin Conjugates</title><p>The synthesis of the conjugates was based on the oxidation-reduction reaction between COS and streptomycin. The COS-Strep conjugates were prepared as previously described [<xref rid="B16-marinedrugs-17-00043" ref-type="bibr">16</xref>]. Briefly, 100 mg COS was first dissolved in 2 mL deionized water, then the pH was adjusted to 4.0 with 0.2 M acetic acid. Then, 525 mg streptomycin was mixed with COS solution at 35 &#x000b0;C with stirring for 1 h in the dark. The synthesis reaction was initialized by the addition of 1 mL 113 mg/mL NaCNBH<sub>3</sub> with stirring for 24 h and terminated with 2 M NaOH. The solution was then dialyzed (molecular weight cut off: 500&#x02013;1000 Da) with deionized water for 48 h. A total of 120 mg of COS-Strep conjugates was collected after lyophilization. </p></sec><sec id="sec2dot3-marinedrugs-17-00043"><title>2.3. Matrix-Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) Mass Spectrometry and Nuclear Magnetic Resonance (NMR) Analysis</title><p>Samples were prepared in 2 mg/mL water solution and filtered with a 0.22 &#x003bc;m syringe filter (Pall, Ann Albor, MI, USA). Then, 1 &#x003bc;L of sample was mixed with the same volume of 2,5-dihydroxybenzoic acid (Sigma-Aldrich, St. Louis, MO, USA) as a sample matrix and air-dried for MALDI-TOF analysis. The analysis was performed on an Autoflex III Smart Beam MALDI-TOF mass spectrometer (Bruker, Bremen, Germany) in the positive ion mode. For <sup>1</sup>H NMR spectral analysis, samples were dissolved in D<sub>2</sub>O (30 mg/mL), and the spectra were carried out on a Bruker AV 500 MHz (Bruker, Karlsruhe, Germany).</p></sec><sec id="sec2dot4-marinedrugs-17-00043"><title>2.4. Biofilm Formation</title><p><italic>P. aeruginosa</italic> biofilms were cultured in 96-well polystyrene microtiter plates as previously described [<xref rid="B16-marinedrugs-17-00043" ref-type="bibr">16</xref>]. Briefly, <italic>P. aeruginosa</italic> was inoculated into LB medium at 28 &#x000b0;C overnight. Then, 100 mL of diluted cell culture (~2 &#x000d7; 10<sup>7</sup> colony-forming units, CFU) was inoculated into each well of a sterile flat-bottomed 96-well polystyrene micro-titer plate. The microtiter plate was incubated statically at 28 &#x000b0;C for 24 h to allow cell attachment and biofilm formation. <italic>S. aureus</italic> and <italic>L. monocytogenes</italic> biofilms were cultured at 37 &#x000b0;C with TSB medium and LB medium, respectively.</p></sec><sec id="sec2dot5-marinedrugs-17-00043"><title>2.5. Biofilm Mass and Viability Analysis</title><p>In order to evaluate the anti-biofilm activity of COS-Strep conjugates, different treatments were conducted as indicated below. Blank LB broth, LB broth with COS, and LB broth with Strep were used as controls. Moreover, LB broth with the mixture of COS and Strep was also included as a control to determine the necessity of the conjugation. After biofilm formation, the 96-well plate was washed three times with phosphate buffer saline (PBS, pH 7.2) to remove the unattached cells. COS-conjugate and different controls were added into the washed biofilms separately, and the 96-well plates were then incubated at 28 &#x000b0;C for 24 h. Biofilms were washed three times with PBS prior to the analysis. The biofilm mass was determined by the crystal violet assay [<xref rid="B17-marinedrugs-17-00043" ref-type="bibr">17</xref>]. The sample was measured for absorbance at 590 nm with a TECAN Infinite M200 PRO multifunction microplate reader (TECAN, Grodig, Austria). To determine the cell viability of the biofilm, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] assay was performed as previously described [<xref rid="B18-marinedrugs-17-00043" ref-type="bibr">18</xref>]. Briefly, 100 &#x000b5;L of 500 &#x003bc;g/mL MTT was added into each well and the plate was incubated for 3 h. MTT was then removed and the formed formazan was dissolved in 100 &#x003bc;L dimethyl sulfoxide (DMSO). Optical density (OD) of samples were measured at 490 nm using a TECAN Infinite M200 PRO multifunction microplate reader (TECAN, Grodig, Austria). The IC<sub>50</sub> of anti-biofilm agents was analyzed using the standard broth microdilution method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. All tests were performed in six replicates for each treatment. Each assay was performed with three biological repeats. </p></sec><sec id="sec2dot6-marinedrugs-17-00043"><title>2.6. Fluorescence Microscopy Assay</title><p>One milliliter of <italic>P. aeruginosa</italic> (~2 &#x000d7; 10<sup>7</sup> CFU) in LB broth was transferred onto 10 &#x000d7; 10 mm glass coverslips (Citoglas, Guangzhou, China) placed on the bottom of the well of 24-well plates and cultivated at 28 &#x000b0;C for 24 h to allow biofilm formation. Unattached cells were removed and coverslips were washed three times with PBS. Formed biofilms were treated with COS-Strep conjugate and controls as indicated above for 24 h at 28 &#x000b0;C. After washing with PBS, 1 &#x000b5;g/mL 4,6-diamidino-2-phenylindole (DAPI, Abbkine, California, America) and 5 &#x000b5;g/mL WGA-FITC (Sigma-Aldrich, St. Louis, MO, USA) were added and incubated in dark for 30 min at 37 &#x000b0;C. Coverslips were then washed and fixed using a 4% paraformaldehyde solution for 30 min at 37 &#x000b0;C. The corresponding fluorescent images were taken by a fluorescent microscope LEICA CTR4000 (Leica, Barnack, Germany).</p></sec><sec id="sec2dot7-marinedrugs-17-00043"><title>2.7. Cellular Toxicity Assay</title><p>Human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were grown in Dulbecco&#x02019;s modified eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 units/mL penicillin under a 5% CO<sub>2</sub> atmosphere at 37 &#x000b0;C. The toxicity assay was conducted as following: HUVEC cells were incubated in 96-well plates (3 &#x000d7; 10<sup>3</sup> cells/well) with Strep or COS-Strep at various concentrations ranging from 50 to 2000 &#x000b5;g/mL for 24 h. The cell toxicity was then evaluated by the MTT assay performed as above. Cell viability (%) was calculated as (absorbance of sample/absorbance of control) &#x000d7; 100.</p></sec><sec id="sec2dot8-marinedrugs-17-00043"><title>2.8. qRT-PCR Analysis</title><sec id="sec2dot8dot1-marinedrugs-17-00043"><title>2.8.1. Isolation of Total RNA</title><p>Two milliliters of bacterial cells (~2 &#x000d7; 10<sup>7</sup> CFU) in LB medium were cultured statically in a 35 &#x000d7; 10 mm style cell culture dish (Corning, New York, NY, USA) for biofilm formation. Drug treatment was conducted as described above. Total RNA was isolated as previously described with some modifications [<xref rid="B18-marinedrugs-17-00043" ref-type="bibr">18</xref>,<xref rid="B19-marinedrugs-17-00043" ref-type="bibr">19</xref>]. Biofilms were dislodged by 1 mL TRIzon reagent of Ultrapure RNA Kit (CWBio, Beijing, China) and the suspension was collected. The suspension was gently sonicated with a 0.5 cm probe with 10 KHz amplitude for 5 min in a noise isolating chamber JY92-IIN (Scientz, Ningbo, China) to release bacteria from biofilms without mechanical cell disruption. Total RNA was then extracted via acidic phenol&#x02013;chloroform extraction. The yield and quality of RNA was determined with NanoDrop 2000C (Thermo, New York, NY, USA).</p></sec><sec id="sec2dot8dot2-marinedrugs-17-00043"><title>2.8.2. Synthesis of cDNA and RT-PCR</title><p>Purified RNA was reverse transcribed into cDNA with HiFiScript cDNA Synthesis Kit (CWBio, Beijing, China). Real-time PCR was performed using the Step One<sup>TM</sup> Real-Time PCR Instrument Thermal Cycling Block (Applied Biosystems Life Technologies, Foster City, California, USA) with the UltraSYBR Mixture Kit (CWBio, Beijing, China). The expression level of each target gene was normalized to that of the 16S rRNA. Each assay was performed in duplicates with three independent biological repeats. Fold change of mRNA level was calculated according to the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method. Primers used for real-time PCR were listed in <xref rid="marinedrugs-17-00043-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot8dot3-marinedrugs-17-00043"><title>2.8.3. Statistical Analysis</title><p>Data are presented as means &#x000b1; SD. A two-tailed Student&#x02019;s <italic>t</italic>-test was performed for the comparison between two groups and one-way analysis of variance (ANOVA) for multiple group analysis. The <italic>p</italic>-value &#x0003c; 0.05 or 0.01 was considered as statistically significantly different. All data were analyzed using Statistical Product and Service Solutions (SPSS) 13.0 software (SPSS Inc., Chicago, IL, USA).</p></sec></sec></sec><sec id="sec3-marinedrugs-17-00043"><title>3. Result</title><sec id="sec3dot1-marinedrugs-17-00043"><title>3.1. Synthesis and Characterization of COS-Strep Conjugates</title><p>The covalent conjugation between streptomycin and chitosan oligosaccharides was achieved by reduction of the resulting Schiff base formed by amino groups in chitosan oligosaccharide and aldehyde groups in streptomycin (<xref ref-type="fig" rid="marinedrugs-17-00043-f001">Figure 1</xref>A), as described [<xref rid="B20-marinedrugs-17-00043" ref-type="bibr">20</xref>]. The product of conjugation was determined by MALDI-TOF-MS analysis (<xref ref-type="fig" rid="marinedrugs-17-00043-f001">Figure 1</xref>B). Peaks had an m/z ratio of 905.6439, 1066.7164, 1227.8052, 1390.9264, 1550.0241, 1711.1075, that represented disaccharides (COS2), trisaccharides (COS3), tetrasccharides (COS4), pentasaccharides (COS5), hexaoses (COS6), heptaoses (COS7) coupled with one streptomycin, respectively. The coupling between streptomycin and COS was evidenced by <sup>1</sup>H NMR analysis (<xref ref-type="app" rid="app1-marinedrugs-17-00043">Figure S2</xref>). The appearance of signals at 2.57 ppm in the spectrum of COS-Strep was likely attributed to methyl protons (<xref ref-type="app" rid="app1-marinedrugs-17-00043">Figure S2A</xref>). Weak signals at 9.66 ppm assigned to aldehyde protons in the spectrum of Strep disappeared in that of COS-Strep (<xref ref-type="app" rid="app1-marinedrugs-17-00043">Figure S2B</xref>). These results strongly suggested the formation of the COS-Strep conjugate.</p></sec><sec id="sec3dot2-marinedrugs-17-00043"><title>3.2. Inhibitory Effects of COS-Strep against <italic>P. aeruginosa</italic> biofilms</title><p>Established <italic>P. aeruginosa</italic> biofilms were treated with COS-Strep to evaluate the anti-biofilm activity of the conjugate. COS-Strep had strongest capability in removing mature biofilms with a minimum effective concentration of 250 &#x000b5;g/mL; COS and Strep had no or weak anti-biofilm activity at 250 &#x000b5;g/mL (<xref ref-type="fig" rid="marinedrugs-17-00043-f002">Figure 2</xref>A). Moreover, COS-Strep showed high efficacy on killing <italic>P. aeruginosa</italic> cells in the cell viability test. The IC<sub>50</sub> value of COS-Strep is 88.35 &#x000b5;g/mL, which is 11-fold lower than that of streptomycin (&#x0003e;1000 &#x000b5;g/mL). For planktonic bacteria, the IC<sub>50</sub> value of COS-Strep was slightly higher than that of streptomycin (<xref ref-type="fig" rid="marinedrugs-17-00043-f002">Figure 2</xref>B). To be noted, a simple mixture with COS did not improve the anti-biofilm activity of streptomycin (<xref ref-type="fig" rid="marinedrugs-17-00043-f002">Figure 2</xref>A). These results suggested that coupling with COS enhanced the antimicrobial efficiency of streptomycin against biofilm of <italic>P. aeruginosa</italic>.</p></sec><sec id="sec3dot3-marinedrugs-17-00043"><title>3.3. The Degree of Polymerization of COS Influenced the Anti-Biofilm Efficacy of COS-Strep Conjugates</title><p>Studies showed that biological activities of COS were largely dependent on its degree of polymerization (DP) [<xref rid="B2-marinedrugs-17-00043" ref-type="bibr">2</xref>,<xref rid="B21-marinedrugs-17-00043" ref-type="bibr">21</xref>,<xref rid="B22-marinedrugs-17-00043" ref-type="bibr">22</xref>]. To investigate whether the DP of COS affects the anti-biofilm capacity of COS-Strep conjugates, two COS products with different DP, including COS (DP 2~8) and COS2 (DP 2~20) as well as Glucosamine and chitosan were conjugated with streptomycin to produce COS-Strep, COS2-Strep, GlcN-Strep and CS-Strep conjugates respectively. Four synthesized conjugates showed enhanced anti-biofilm activities against biofilms than streptomycin alone at 250 &#x003bc;g/mL (<xref ref-type="fig" rid="marinedrugs-17-00043-f003">Figure 3</xref>). Moreover, two COS-streptomycin conjugates, COS-strep and COS2-Strep, removed more than 70% biofilms mass, while streptomycin was only capable of removing 22%.</p><p>On the contrary, GlcN-Strep and CS-Strep conjugates only slightly enhanced the anti-biofilm activity compared to streptomycin (<xref ref-type="fig" rid="marinedrugs-17-00043-f003">Figure 3</xref>). Among the two COS-Strep conjugates, COS2-Strep exhibited the highest anti-biofilm activity. These results indicated that the anti-biofilm activity of streptomycin can be enhanced by conjugating with COS rather than its structurally similar polymers or monosaccharide component. Furthermore, the anti-biofilm activity of COS-Strep conjugates was affected by the degree of polymerization of COS used in the conjugation process. </p></sec><sec id="sec3dot4-marinedrugs-17-00043"><title>3.4. Coupling with COS Did not Improve the Anti-Biofilm Activity of Streptomycin on <italic>S. aureus</italic> and <italic>L. monocytogenes</italic></title><p>To investigate the anti-biofilm activity of COS-Strep on other bacteria, we assessed the activity of COS-Strep on mature biofilms of <italic>S. aureus</italic> and <italic>L. monocytogenes</italic>, which are Gram-positive opportunistic human pathogens. COS-Strep or Strep alone did not show inhibition effects against biofilms of tested strains at 250 &#x003bc;g/mL (<xref ref-type="fig" rid="marinedrugs-17-00043-f004">Figure 4</xref>).</p></sec><sec id="sec3dot5-marinedrugs-17-00043"><title>3.5. Cellular Toxicity</title><p>HUVEC cells were used to determine potential side effects of the COS-Strep conjugate in cell viability analysis. Same as streptomycin (<xref ref-type="fig" rid="marinedrugs-17-00043-f005">Figure 5</xref>A), COS-Strep had no obvious effects on the growth of the mammalian cell strain at 1 mg/mL (<xref ref-type="fig" rid="marinedrugs-17-00043-f005">Figure 5</xref>B).</p></sec><sec id="sec3dot6-marinedrugs-17-00043"><title>3.6. Influence on <italic>P. aeruginosa</italic> Biofilm Related Gene Expressions under the COS-Strep Conjugate Treatment</title><p>To explore the mechanism of the antibacterial activity of COS-Strep on <italic>P. aeruginosa</italic> biofilms, expression levels of several genes related to biofilm formation or drug-resistance were determined. Genes including <italic>pslA</italic>, <italic>pelA</italic>, and <italic>algD</italic>, which are related to biosynthesis of biofilm exopolysaccharides Psl, Pel, and alignate [<xref rid="B23-marinedrugs-17-00043" ref-type="bibr">23</xref>,<xref rid="B24-marinedrugs-17-00043" ref-type="bibr">24</xref>]; <italic>MexY</italic>, and <italic>mexZ</italic> which encode proteins involved in MexX-MexY drug efflux pump system [<xref rid="B25-marinedrugs-17-00043" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-17-00043" ref-type="bibr">26</xref>]; and <italic><styled-content style="color:#231F20">cdrA</styled-content></italic> which encode proteins to mediate bacterial aggregation and biofilm adherence [<xref rid="B27-marinedrugs-17-00043" ref-type="bibr">27</xref>]<styled-content style="color:#231F20">, </styled-content>were selected as targets. Streptomycin treatment greatly upregulated the expression of <italic>mexY</italic> by 1.9 fold in biofilm cells, suggesting the activation of the MexX-MexY drug efflux pump system (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>A). On the contrary, COS-Strep treatment slightly down-regulated the expression of <italic>mexY</italic> (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>A), likely through upregulating the expression of its suppressor, <italic>mexZ</italic> (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>B). Thus, COS-Strep treatment did not upregulate or even suppress the MexX-MexY system which was activated by streptomycin. Genes <italic>pelA</italic> and <italic>algD</italic> were also down-regulated by 0.68 and 0.75 fold, respectively with COS-Strep treatment compared to the control or streptomycin treated group (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>C,D). On the other hand, the expression level of <italic>pslA</italic> and <italic>cdrA</italic> remained unaffected under COS-Strep treatment (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>E,F). Therefore, the anti-biofilm activity of COS-Strep might be because of its ability to suppress the activation of the drug efflux pump system and the biosynthesis of specific exopolysaccharides. </p></sec><sec id="sec3dot7-marinedrugs-17-00043"><title>3.7. COS-Strep Treatment Reduced Biofilm Exopolysaccharides of <italic>P. aeruginosa</italic></title><p>In order to investigate the effect of COS-Strep on biofilm exopolysaccharides, we stained the biofilm with FITC labeled wheat germ agglutinin (WGA) lectin which bound to exopolysaccharide, and DAPI. We observed the reduction of signals with WGA-FITC and DAPI staining after COS-Strep treatment, suggesting its influence on both biofilm cell viability and exopolysaccharide (<xref ref-type="fig" rid="marinedrugs-17-00043-f007">Figure 7</xref>).</p></sec></sec><sec id="sec4-marinedrugs-17-00043"><title>4. Discussion</title><p>Streptomycin is a common aminoglycoside antibiotic which is used to treat a number of bacterial infections. However, pathogens in biofilms could greatly increase their drug resistance. It has been previously reported that chitosan coupling with streptomycin (CS-Strep) could eradicate biofilms of several Gram-positive organisms, but barely affect that of Gram-negative organisms such as <italic>P. aeruginosa</italic> [<xref rid="B11-marinedrugs-17-00043" ref-type="bibr">11</xref>]. However, the underlying molecular mechanism of the CS-Strep remained unclear. Moreover, poor water-solubility of CS-Strep might restrict its applications on anti-infection therapy. In this study, we prepared the chitosan oligosaccharide-streptomycin conjugate (COS-Strep), which has an improved water-solubility. Our data showed that the COS-Strep conjugate was much more effective in eradicating established biofilms of <italic>P. aeruginosa</italic> than streptomycin alone or their simple mixture (<xref ref-type="fig" rid="marinedrugs-17-00043-f002">Figure 2</xref>). The efficacy of the anti-biofilm activity was affected by the DP of COS used for conjugation (<xref ref-type="fig" rid="marinedrugs-17-00043-f003">Figure 3</xref>). The activity of COS-Strep on the <italic>P. aeruginosa</italic> biofilm was likely through inhibiting response of the MexX-MexY drug efflux pump system and synthesis of biofilm exopolysaccharides (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>). </p><p>Surprisingly, unlike CS-Strep, the COS-Strep conjugate did not show an obvious anti-biofilm activity on Gram-positive organisms such as <italic>S. aureus</italic> and <italic>L. monocytogenes</italic> (<xref ref-type="fig" rid="marinedrugs-17-00043-f004">Figure 4</xref>). However, COS-Strep effectively inhibited against <italic>P. aeruginosa</italic> biofilms (<xref ref-type="fig" rid="marinedrugs-17-00043-f002">Figure 2</xref>), suggesting their opposite effects on tested organisms. Although COS and chitosan shared structural similarity, both showed anti-biofilm activity when conjugating with streptomycin, the mechanism behind the antimicrobial activity of the two conjugates might be different. Previous studies on the antibacterial activity of chitosan and COS indicated that chitosan had stronger bactericidal effects with gram-positive bacteria than gram-negative bacteria [<xref rid="B28-marinedrugs-17-00043" ref-type="bibr">28</xref>], while COS showed better activity against gram-negative bacteria [<xref rid="B29-marinedrugs-17-00043" ref-type="bibr">29</xref>]. These diverse activities might be relevant to the difference in the composition of cell walls and biofilm matrix of different organisms or the antibacterial action mode of COS and chitosan. The selective anti-biofilm activity of the COS-Strep conjugate on <italic>P. aeruginosa</italic> was likely determined by the glycan part of the conjugate, especially considering that streptomycin was not a suitable antibiotic for treatment of <italic>P. aeruginosa</italic> infection. </p><p><italic>P. aeruginosa</italic> is a major clinical opportunistic pathogen. There is an increasing awareness of the important role of <italic>P. aeruginosa</italic> biofilm infections associated with specific tissue and implants such as the mucus plugs of the cystic fibrosis (CF) lungs, catheters, and contact lenses [<xref rid="B30-marinedrugs-17-00043" ref-type="bibr">30</xref>,<xref rid="B31-marinedrugs-17-00043" ref-type="bibr">31</xref>]. Antibiotic treatments for <italic>P. aeruginosa</italic> sometimes are inefficient due to its ability to form biofilms on various organic and inorganic surfaces. Studies have shown that the MexX-MexY drug efflux pump system plays a vital part in the intrinsic resistance of <italic>P. aeruginosa</italic> to aminoglycosides. The MexX-MexY system was regulated by <italic>mexZ</italic> which was a repressor of <italic>mexY</italic> expression [<xref rid="B25-marinedrugs-17-00043" ref-type="bibr">25</xref>,<xref rid="B26-marinedrugs-17-00043" ref-type="bibr">26</xref>]. To explore whether the antibacterial activity of COS-Strep on <italic>P. aeruginosa</italic> biofilms was through affecting MexX-MexY drug efflux pump system, the expression levels of several genes related to MexX-MexY drug efflux pump were determined under the treatment of COS-Strep. The results showed that COS-Strep did not induce the activation of the MexX-MexY system compared to streptomycin, (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>). This result suggested that the COS-Strep conjugate suppressed the response of this drug-resistance machinery. The mechanism behind this activity requires further investigation.</p><p>We also found that expressions of exopolysaccharide biosynthesis genes were influenced under the COS-Strep treatment. In <italic>P. aeruginosa</italic> biofilms, Psl, Pel and alginate exopolysaccharides served as key structural components of the biofilm matrix [<xref rid="B32-marinedrugs-17-00043" ref-type="bibr">32</xref>]. Previous studies indicated that Psl and alginate were required for formation of biofilms, whereas Pel played an important role in controlling biofilm cell density and/or the compactness of biofilms [<xref rid="B33-marinedrugs-17-00043" ref-type="bibr">33</xref>]. Our studies showed that the expression of <italic>pelA</italic> and <italic>algD</italic> genes were suppressed under the treatment of COS-Strep (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>C,D), but not <italic>pslA</italic> and <italic>cdrA</italic> (<xref ref-type="fig" rid="marinedrugs-17-00043-f006">Figure 6</xref>E,F). CdrA, a biofilm matrix protein, is related to extracellular adhesion and promotes tight cellular interactions in biofilm aggregates [<xref rid="B27-marinedrugs-17-00043" ref-type="bibr">27</xref>]. The result indicated COS-Strep might impair the structural integrity of the biofilm by inhibiting the biosynthesis of Pel and alginate exopolysaccharides. Pel is a positively charged polysaccharide composed of partially acetylated 1-4 glycosidic linkages of <italic>N</italic>-acetylgalactosamine and <italic>N</italic>-acetylglucosamine [<xref rid="B34-marinedrugs-17-00043" ref-type="bibr">34</xref>]. WGA lectin usually recognizes <italic>N</italic>-acetylglucosamine-containing glycans. To further explore the possible influence of COS-Strep on biofilm exopolysaccharides, we determined the biofilm structure after drug treatment under a fluorescence microscope, using FITC (green fluorescent bioconjugates) labeled WGA lectin. Our results showed a significant reduction of green fluorescent signals after treatment with COS-Strep (<xref ref-type="fig" rid="marinedrugs-17-00043-f007">Figure 7</xref>). It further supported that COS-Strep affected the structural integrity of biofilm exopolysaccharides. </p></sec><sec id="sec5-marinedrugs-17-00043"><title>5. Conclusions</title><p>In summary, our result highlighted that chitosan oligosaccharide coupling greatly increased the susceptibility of <italic>P. aeruginosa</italic> biofilms to streptomycin. COS-Strep treatments might suppress the response of the drug efflux pump system and inhibited the biosynthesis of Pel and alginate exopolysaccharides. Given chitosan oligosaccharide gain considerable attention as a biomaterial, due to its good water-solubility and low toxicity, this novel strategy might open up a new avenue to overcome the inherent resistance of biofilms to antibiotics, and come into wide use for combating biofilm-related problems in industrial and medical areas.</p></sec></body><back><ack><title>Acknowledgments</title><p>Thanks to Yalu Yan for language polishing of this paper. Thanks to Jianjun Li for analyzing the NMR results.</p></ack><app-group><app id="app1-marinedrugs-17-00043"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="http://www.mdpi.com/1660-3397/17/1/43/s1">http://www.mdpi.com/1660-3397/17/1/43/s1</uri>. Figure S1. The results of HPLC analysis of COS (DP2-8) and COS (DP 2-20) (A) and LC-MS results of COS and COS2; Figure S2. <sup>1</sup>H NMR spectra of COS, streptomycin, COS+Strep and COS-Strep conjugates. The Freeze-dried COS, Strep, the COS-Strep conjugate and a mixture of two molecules (mass ratio 1:1) were dissolved in deuterated water to a final concentration of 30mg/mL respectively. The spectra were recorded at 298 K in deuterium oxide on a Varian VNMRS-500 NMR spectrometer. Red arrow represented the methyl protons singal at 2.57 ppm in COS-Strep conjugates (A). Red arrow represented aldehyde proton singal at 9.66 ppm that was the functional group of streptomycin (B).</p><supplementary-material content-type="local-data" id="marinedrugs-17-00043-s001"><media xlink:href="marinedrugs-17-00043-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Y.D. and Z.A.W. designed the study. R.L. and X.Y. were responsible for the acquisition of data. Z.A.W. and R.L. interpreted the experimental data. R.L. and Z.A.W. were the major contributors in drafting and revising the manuscript. Z.A.W. was final approval of the version to be submitted. All authors read and approved the final manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by [National Natural Science Fund, China] grant number [NO. 31670809], [the Key Research Program of the Chinese Academy of Sciences] grant number [No. KFZD-SW-218] and [the Open Project Program of the Collaborative Innovation Center of Modern Bio-Manufacture, Anhui University] grant number [No. BM2016004].</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-17-00043"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoodley</surname><given-names>P.</given-names></name><name><surname>Sauer</surname><given-names>K.</given-names></name><name><surname>Davies</surname><given-names>D.G.</given-names></name><name><surname>Costerton</surname><given-names>W.J.</given-names></name></person-group><article-title>Biofilms as Complex Differentiated Communities</article-title><source>Annu. Rev. Microbiol.</source><year>2002</year><volume>56</volume><fpage>187</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.56.012302.160705</pub-id><?supplied-pmid 12142477?><pub-id pub-id-type="pmid">12142477</pub-id></element-citation></ref><ref id="B2-marinedrugs-17-00043"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>R.P.</given-names></name><name><surname>Taffs</surname><given-names>R.</given-names></name><name><surname>Davison</surname><given-names>W.M.</given-names></name><name><surname>Stewart</surname><given-names>P.S.</given-names></name></person-group><article-title>Anti-biofilm properties of chitosan-coated surfaces</article-title><source>J. Biomater. Sci. Polym. Ed.</source><year>2008</year><volume>19</volume><fpage>1035</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1163/156856208784909372</pub-id><?supplied-pmid 18644229?><pub-id pub-id-type="pmid">18644229</pub-id></element-citation></ref><ref id="B3-marinedrugs-17-00043"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebeaux</surname><given-names>D.</given-names></name><name><surname>Ghigo</surname><given-names>J.M.</given-names></name><name><surname>Beloin</surname><given-names>C.</given-names></name></person-group><article-title>Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2014</year><volume>78</volume><fpage>510</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00013-14</pub-id><pub-id pub-id-type="pmid">25184564</pub-id></element-citation></ref><ref id="B4-marinedrugs-17-00043"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandakumar</surname><given-names>V.</given-names></name><name><surname>Chittaranjan</surname><given-names>S.</given-names></name><name><surname>Kurian</surname><given-names>V.M.</given-names></name><name><surname>Doble</surname><given-names>M.</given-names></name></person-group><article-title>Characteristics of bacterial biofilm associated with implant material in clinical practice</article-title><source>Polym. J.</source><year>2012</year><volume>45</volume><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1038/pj.2012.130</pub-id></element-citation></ref><ref id="B5-marinedrugs-17-00043"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miquel</surname><given-names>S.</given-names></name><name><surname>Lagrafeuille</surname><given-names>R.</given-names></name><name><surname>Souweine</surname><given-names>B.</given-names></name><name><surname>Forestier</surname><given-names>C.</given-names></name></person-group><article-title>Anti-biofilm Activity as a Health Issue</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><fpage>592</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2016.00592</pub-id><?supplied-pmid 27199924?><pub-id pub-id-type="pmid">27199924</pub-id></element-citation></ref><ref id="B6-marinedrugs-17-00043"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengzhuang</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Ciofu</surname><given-names>O.</given-names></name><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Hoiby</surname><given-names>N.</given-names></name></person-group><article-title>Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid <italic>Pseudomonas aeruginosa</italic> biofilms</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>4469</fpage><lpage>4474</lpage><pub-id pub-id-type="doi">10.1128/AAC.00126-11</pub-id><?supplied-pmid 21670181?><pub-id pub-id-type="pmid">21670181</pub-id></element-citation></ref><ref id="B7-marinedrugs-17-00043"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Ciofu</surname><given-names>O.</given-names></name><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Hoiby</surname><given-names>N.</given-names></name></person-group><article-title>In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in <italic>Pseudomonas aeruginosa</italic> biofilm infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>2683</fpage><lpage>2690</lpage><pub-id pub-id-type="pmid">22354300</pub-id></element-citation></ref><ref id="B8-marinedrugs-17-00043"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Moser</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H.Z.</given-names></name><name><surname>Hoiby</surname><given-names>N.</given-names></name><name><surname>Song</surname><given-names>Z.J.</given-names></name></person-group><article-title>Strategies for combating bacterial biofilm infections</article-title><source>Int. J. Oral Sci.</source><year>2015</year><volume>7</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ijos.2014.65</pub-id><?supplied-pmid 25504208?><pub-id pub-id-type="pmid">25504208</pub-id></element-citation></ref><ref id="B9-marinedrugs-17-00043"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechinger</surname><given-names>B.</given-names></name><name><surname>Gorr</surname><given-names>S.U.</given-names></name></person-group><article-title>Antimicrobial Peptides: Mechanisms of Action and Resistance</article-title><source>J. Dent. Res.</source><year>2017</year><volume>96</volume><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1177/0022034516679973</pub-id><?supplied-pmid 27872334?><pub-id pub-id-type="pmid">27872334</pub-id></element-citation></ref><ref id="B10-marinedrugs-17-00043"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>P.S.</given-names></name><name><surname>Costerton</surname><given-names>J.W.</given-names></name></person-group><article-title>Antibiotic resistance of bacteria in biofilms</article-title><source>Lancet (Lond. Engl.)</source><year>2001</year><volume>358</volume><fpage>135</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05321-1</pub-id></element-citation></ref><ref id="B11-marinedrugs-17-00043"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Mu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Duan</surname><given-names>J.</given-names></name></person-group><article-title>Chitosan coupling makes microbial biofilms susceptible to antibiotics</article-title><source>Sci. Rep.</source><year>2013</year><volume>3</volume><fpage>3364</fpage><pub-id pub-id-type="doi">10.1038/srep03364</pub-id><pub-id pub-id-type="pmid">24284335</pub-id></element-citation></ref><ref id="B12-marinedrugs-17-00043"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tre-Hardy</surname><given-names>M.</given-names></name><name><surname>Vanderbist</surname><given-names>F.</given-names></name><name><surname>Traore</surname><given-names>H.</given-names></name><name><surname>Devleeschouwer</surname><given-names>M.J.</given-names></name></person-group><article-title>In vitro activity of antibiotic combinations against <italic>Pseudomonas aeruginosa</italic> biofilm and planktonic cultures</article-title><source>Int. J. Antimicrob. Agents</source><year>2008</year><volume>31</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.12.005</pub-id><?supplied-pmid 18280117?><pub-id pub-id-type="pmid">18280117</pub-id></element-citation></ref><ref id="B13-marinedrugs-17-00043"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thadathil</surname><given-names>N.</given-names></name><name><surname>Velappan</surname><given-names>S.P.</given-names></name></person-group><article-title>Recent developments in chitosanase research and its biotechnological applications: A review</article-title><source>Food Chem.</source><year>2014</year><volume>150</volume><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2013.10.083</pub-id><?supplied-pmid 24360467?><pub-id pub-id-type="pmid">24360467</pub-id></element-citation></ref><ref id="B14-marinedrugs-17-00043"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muanprasat</surname><given-names>C.</given-names></name><name><surname>Chatsudthipong</surname><given-names>V.</given-names></name></person-group><article-title>Chitosan oligosaccharide: Biological activities and potential therapeutic applications</article-title><source>Pharmacol. Ther.</source><year>2017</year><volume>170</volume><fpage>80</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.10.013</pub-id><?supplied-pmid 27773783?><pub-id pub-id-type="pmid">27773783</pub-id></element-citation></ref><ref id="B15-marinedrugs-17-00043"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Jiao</surname><given-names>S.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.A.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name></person-group><article-title>Conjugation of Inulin Improves Anti-Biofilm Activity of Chitosan</article-title><source>Mar. Drugs</source><year>2018</year><volume>16</volume><elocation-id>151</elocation-id><pub-id pub-id-type="doi">10.3390/md16050151</pub-id><?supplied-pmid 29734657?><pub-id pub-id-type="pmid">29734657</pub-id></element-citation></ref><ref id="B16-marinedrugs-17-00043"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitts</surname><given-names>B.</given-names></name><name><surname>Hamilton</surname><given-names>M.A.</given-names></name><name><surname>Zelver</surname><given-names>N.</given-names></name><name><surname>Stewart</surname><given-names>P.S.</given-names></name></person-group><article-title>A microtiter-plate screening method for biofilm disinfection and removal</article-title><source>J. Microbiol. Methods</source><year>2003</year><volume>54</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/S0167-7012(03)00034-4</pub-id><pub-id pub-id-type="pmid">12782382</pub-id></element-citation></ref><ref id="B17-marinedrugs-17-00043"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T.</given-names></name></person-group><article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title><source>J. Immunol. Methods</source><year>1983</year><volume>65</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(83)90303-4</pub-id><pub-id pub-id-type="pmid">6606682</pub-id></element-citation></ref><ref id="B18-marinedrugs-17-00043"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>J.L.</given-names></name><name><surname>van Delden</surname><given-names>C.</given-names></name><name><surname>Perron</surname><given-names>K.</given-names></name><name><surname>Kohler</surname><given-names>T.</given-names></name></person-group><article-title>Analysis of antibiotic resistance gene expression in <italic>Pseudomonas aeruginosa</italic> by quantitative real-time-PCR</article-title><source>FEMS Microbiol. Lett.</source><year>2006</year><volume>254</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2005.00008.x</pub-id><pub-id pub-id-type="pmid">16445748</pub-id></element-citation></ref><ref id="B19-marinedrugs-17-00043"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D.Q.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Duan</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>Sodium houttuyfonate inhibits biofilm formation and alginate biosynthesis-associated gene expression in a clinical strain of <italic>Pseudomonas aeruginosa</italic> in vitro</article-title><source>Exp. Ther. Med.</source><year>2015</year><volume>10</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.3892/etm.2015.2562</pub-id><pub-id pub-id-type="pmid">26622388</pub-id></element-citation></ref><ref id="B20-marinedrugs-17-00043"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djordjevic</surname><given-names>D.</given-names></name><name><surname>Wiedmann</surname><given-names>M.</given-names></name><name><surname>McLandsborough</surname><given-names>L.A.</given-names></name></person-group><article-title>Microtiter plate assay for assessment of Listeria monocytogenes biofilm formation</article-title><source>Appl. Environ. Microbiol.</source><year>2002</year><volume>68</volume><fpage>2950</fpage><lpage>2958</lpage><pub-id pub-id-type="doi">10.1128/AEM.68.6.2950-2958.2002</pub-id><pub-id pub-id-type="pmid">12039754</pub-id></element-citation></ref><ref id="B21-marinedrugs-17-00043"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquantonio</surname><given-names>G.</given-names></name><name><surname>Greco</surname><given-names>C.</given-names></name><name><surname>Prenna</surname><given-names>M.</given-names></name><name><surname>Ripa</surname><given-names>C.</given-names></name><name><surname>Vitali</surname><given-names>L.A.</given-names></name><name><surname>Petrelli</surname><given-names>D.</given-names></name><name><surname>Di Luca</surname><given-names>M.C.</given-names></name><name><surname>Ripa</surname><given-names>S.</given-names></name></person-group><article-title>Antibacterial activity and anti-biofilm effect of chitosan against strains of Streptococcus mutans isolated in dental plaque</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2008</year><volume>21</volume><fpage>993</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1177/039463200802100424</pub-id><pub-id pub-id-type="pmid">19144285</pub-id></element-citation></ref><ref id="B22-marinedrugs-17-00043"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>E.M.</given-names></name><name><surname>Silva</surname><given-names>S.</given-names></name><name><surname>Tavaria</surname><given-names>F.K.</given-names></name><name><surname>Pintado</surname><given-names>M.M.</given-names></name></person-group><article-title>Study of the effects of chitosan upon Streptococcus mutans adherence and biofilm formation</article-title><source>Anaerobe</source><year>2013</year><volume>20</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.anaerobe.2013.02.002</pub-id><?supplied-pmid 23454497?><pub-id pub-id-type="pmid">23454497</pub-id></element-citation></ref><ref id="B23-marinedrugs-17-00043"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>E.E.</given-names></name><name><surname>Wozniak</surname><given-names>D.J.</given-names></name></person-group><article-title>Pseudomonas biofilm matrix composition and niche biology</article-title><source>FEMS Microbiol. Rev.</source><year>2012</year><volume>36</volume><fpage>893</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2011.00322.x</pub-id><?supplied-pmid 22212072?><pub-id pub-id-type="pmid">22212072</pub-id></element-citation></ref><ref id="B24-marinedrugs-17-00043"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>M.J.</given-names></name><name><surname>Nivens</surname><given-names>D.E.</given-names></name><name><surname>Weadge</surname><given-names>J.T.</given-names></name><name><surname>Howell</surname><given-names>P.L.</given-names></name></person-group><article-title>Biosynthesis of the <italic>Pseudomonas aeruginosa</italic> Extracellular Polysaccharides, Alginate, Pel, and Psl</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2011.00167</pub-id><?supplied-pmid 21991261?><pub-id pub-id-type="pmid">21991261</pub-id></element-citation></ref><ref id="B25-marinedrugs-17-00043"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aires</surname><given-names>J.R.</given-names></name><name><surname>Kohler</surname><given-names>T.</given-names></name><name><surname>Nikaido</surname><given-names>H.</given-names></name><name><surname>Plesiat</surname><given-names>P.</given-names></name></person-group><article-title>Involvement of an active efflux system in the natural resistance of <italic>Pseudomonas aeruginosa</italic> to aminoglycosides</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>2624</fpage><lpage>2628</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.11.2624</pub-id><pub-id pub-id-type="pmid">10543738</pub-id></element-citation></ref><ref id="B26-marinedrugs-17-00043"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westbrock-Wadman</surname><given-names>S.</given-names></name><name><surname>Sherman</surname><given-names>D.R.</given-names></name><name><surname>Hickey</surname><given-names>M.J.</given-names></name><name><surname>Coulter</surname><given-names>S.N.</given-names></name><name><surname>Zhu</surname><given-names>Y.Q.</given-names></name><name><surname>Warrener</surname><given-names>P.</given-names></name><name><surname>Nguyen</surname><given-names>L.Y.</given-names></name><name><surname>Shawar</surname><given-names>R.M.</given-names></name><name><surname>Folger</surname><given-names>K.R.</given-names></name><name><surname>Stover</surname><given-names>C.K.</given-names></name></person-group><article-title>Characterization of a <italic>Pseudomonas aeruginosa</italic> efflux pump contributing to aminoglycoside impermeability</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>2975</fpage><lpage>2983</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.12.2975</pub-id><?supplied-pmid 10582892?><pub-id pub-id-type="pmid">10582892</pub-id></element-citation></ref><ref id="B27-marinedrugs-17-00043"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichhardt</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Passos da Silva</surname><given-names>D.</given-names></name><name><surname>Wozniak</surname><given-names>D.J.</given-names></name><name><surname>Parsek</surname><given-names>M.R.</given-names></name></person-group><article-title>CdrA Interactions within the <italic>Pseudomonas aeruginosa</italic> Biofilm Matrix Safeguard It from Proteolysis and Promote Cellular Packing</article-title><source>MBio</source><year>2018</year><volume>9</volume><fpage>e01376-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01376-18</pub-id><?supplied-pmid 30254118?><pub-id pub-id-type="pmid">30254118</pub-id></element-citation></ref><ref id="B28-marinedrugs-17-00043"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>No</surname><given-names>H.K.</given-names></name><name><surname>Park</surname><given-names>N.Y.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Meyers</surname><given-names>S.P.</given-names></name></person-group><article-title>Antibacterial activity of chitosans and chitosan oligomers with different molecular weights</article-title><source>Int J. Food Microbiol</source><year>2002</year><volume>74</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0168-1605(01)00717-6</pub-id><pub-id pub-id-type="pmid">11929171</pub-id></element-citation></ref><ref id="B29-marinedrugs-17-00043"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S.B.</given-names></name><name><surname>Chen</surname><given-names>S.H.</given-names></name><name><surname>Peng</surname><given-names>K.C.</given-names></name></person-group><article-title>Preparation of antibacterial chito-oligosaccharide by altering the degree of deacetylation of beta-chitosan in a Trichoderma harzianum chitinase-hydrolysing process</article-title><source>J. Sci. Food Agric.</source><year>2009</year><volume>89</volume><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1002/jsfa.3432</pub-id></element-citation></ref><ref id="B30-marinedrugs-17-00043"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P.K.</given-names></name><name><surname>Schaefer</surname><given-names>A.L.</given-names></name><name><surname>Parsek</surname><given-names>M.R.</given-names></name><name><surname>Moninger</surname><given-names>T.O.</given-names></name><name><surname>Welsh</surname><given-names>M.J.</given-names></name><name><surname>Greenberg</surname><given-names>E.P.</given-names></name></person-group><article-title>Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>762</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/35037627</pub-id><pub-id pub-id-type="pmid">11048725</pub-id></element-citation></ref><ref id="B31-marinedrugs-17-00043"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delissalde</surname><given-names>F.</given-names></name><name><surname>Amabile-Cuevas</surname><given-names>C.F.</given-names></name></person-group><article-title>Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and non-producing clinical isolates of <italic>Pseudomonas aeruginosa</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2004</year><volume>24</volume><fpage>405</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.03.012</pub-id><?supplied-pmid 15380270?><pub-id pub-id-type="pmid">15380270</pub-id></element-citation></ref><ref id="B32-marinedrugs-17-00043"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colvin</surname><given-names>K.M.</given-names></name><name><surname>Irie</surname><given-names>Y.</given-names></name><name><surname>Tart</surname><given-names>C.S.</given-names></name><name><surname>Urbano</surname><given-names>R.</given-names></name><name><surname>Whitney</surname><given-names>J.C.</given-names></name><name><surname>Ryder</surname><given-names>C.</given-names></name><name><surname>Howell</surname><given-names>P.L.</given-names></name><name><surname>Wozniak</surname><given-names>D.J.</given-names></name><name><surname>Parsek</surname><given-names>M.R.</given-names></name></person-group><article-title>The Pel and Psl polysaccharides provide <italic>Pseudomonas aeruginosa</italic> structural redundancy within the biofilm matrix</article-title><source>Environ. Microbiol</source><year>2012</year><volume>14</volume><fpage>1913</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1111/j.1462-2920.2011.02657.x</pub-id><?supplied-pmid 22176658?><pub-id pub-id-type="pmid">22176658</pub-id></element-citation></ref><ref id="B33-marinedrugs-17-00043"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafoor</surname><given-names>A.</given-names></name><name><surname>Hay</surname><given-names>I.D.</given-names></name><name><surname>Rehm</surname><given-names>B.H.</given-names></name></person-group><article-title>Role of exopolysaccharides in <italic>Pseudomonas aeruginosa</italic> biofilm formation and architecture</article-title><source>Appl. Environ. Microbiol.</source><year>2011</year><volume>77</volume><fpage>5238</fpage><lpage>5246</lpage><pub-id pub-id-type="doi">10.1128/AEM.00637-11</pub-id><pub-id pub-id-type="pmid">21666010</pub-id></element-citation></ref><ref id="B34-marinedrugs-17-00043"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>L.K.</given-names></name><name><surname>Storek</surname><given-names>K.M.</given-names></name><name><surname>Ledvina</surname><given-names>H.E.</given-names></name><name><surname>Coulon</surname><given-names>C.</given-names></name><name><surname>Marmont</surname><given-names>L.S.</given-names></name><name><surname>Sadovskaya</surname><given-names>I.</given-names></name><name><surname>Secor</surname><given-names>P.R.</given-names></name><name><surname>Tseng</surname><given-names>B.S.</given-names></name><name><surname>Scian</surname><given-names>M.</given-names></name><name><surname>Filloux</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the <italic>Pseudomonas aeruginosa</italic> biofilm matrix</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>11353</fpage><lpage>11358</lpage><pub-id pub-id-type="doi">10.1073/pnas.1503058112</pub-id><?supplied-pmid 26311845?><pub-id pub-id-type="pmid">26311845</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-17-00043-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Reaction scheme of the chitosan oligosaccharides-streptomycin (COS-Strep) conjugate synthesis and characterization of synthesized products. Schematic diagram represented the reaction to synthesize of COS-Strep conjugates (<bold>A</bold>). The mass spectrum of COS-Strep conjugates by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (<bold>B</bold>).</p></caption><graphic xlink:href="marinedrugs-17-00043-g001"/></fig><fig id="marinedrugs-17-00043-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The anti-biofilm activity of COS-Strep conjugates on mature <italic>Pseudomonas aeruginosa</italic> biofilms. <italic>P. aeruginosa</italic> mature biofilms were treated with LB broth containing 250 &#x003bc;g/mL COS, streptomycin, COS-Strep and their mixture (COS + Strep, 250 + 250 &#x003bc;g/mL) for 24 h respectively. Blank medium was used as a control. The biofilm biomass was determined by crystal violet staining and normalized to the control (<bold>A</bold>). Established biofilms were exposed to COS-Strep with a series of concentrations for 24 h and the cell viability of <italic>P. aeruginosa</italic> was determined by MTT assay (<bold>B</bold>). Data are represented as means &#x000b1; SD (<italic>n</italic> = 6). * <italic>p</italic> &#x0003c; 0.05 or ** <italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="marinedrugs-17-00043-g002"/></fig><fig id="marinedrugs-17-00043-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The anti-biofilm activity of COS-Strep with different polymerization degrees. Mature <italic>P. aeruginosa</italic> biofilms were exposed to 250 &#x003bc;g/mL COS-Strep, COS2-Strep, GlcN-Strep and chitosan-streptomycin conjugate (CS-Strep) for 24 h. The residual biofilm mass relative to the control was assessed by the crystal violet staining assay. Data are represented as means &#x000b1; SD (<italic>n</italic> = 6). * <italic>p</italic> &#x0003c; 0.05; ** <italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="marinedrugs-17-00043-g003"/></fig><fig id="marinedrugs-17-00043-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The anti-biofilm activity of COS-Strep conjugate on Gram-positive bacterial biofilms. <italic>Staphylococcus aureus</italic> (<bold>A</bold>) and <italic>Listeria monocytogenes</italic> (<bold>B</bold>) mature biofilms were exposed to COS-Strep for 24 h at 250 &#x003bc;g/mL. The biofilm mass was determined by crystal violet staining assay. Data are represented as means &#x000b1; SD (<italic>n</italic> = 6).</p></caption><graphic xlink:href="marinedrugs-17-00043-g004"/></fig><fig id="marinedrugs-17-00043-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The cell toxicity of streptomycin (<bold>A</bold>) and COS-Strep (<bold>B</bold>) on HUVEC cells. Data are represented as means &#x000b1; SD (<italic>n</italic> = 8). * <italic>p</italic> &#x0003c; 0.05 or ** <italic>p</italic> &#x0003c; 0.01, compared to the control group.</p></caption><graphic xlink:href="marinedrugs-17-00043-g005"/></fig><fig id="marinedrugs-17-00043-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Differences in the expression levels of biofilm-related genes of <italic>P. aeruginosa</italic>. <italic>mexY</italic> (<bold>A</bold>), <italic>mexZ</italic> (<bold>B</bold>), <italic>pelA</italic> (<bold>C</bold>), <italic>algD</italic> (<bold>D</bold>), <italic>pslA</italic> (<bold>E</bold>), <italic>and cdrA</italic> (<bold>F</bold>) in <italic>P. aeruginosa</italic> following COS-Strep or streptomycin treatment. Data are represented as means &#x000b1; SD (<italic>n</italic> = 3). * <italic>p</italic> &#x0003c; 0.05; ** <italic>p</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="marinedrugs-17-00043-g006"/></fig><fig id="marinedrugs-17-00043-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>COS-Strep affected biofilm exopolysaccharides of <italic>P. aeruginosa</italic>. Drug treated biofilms were observed by fluorescence image assay. Shown are single-channel images of signal derived from staining with 4,6-diamidino-2-phenylindole (DAPI) (nucleus, blue, upper panel) and WGA-FITC (exopolysaccharide, green, lower panel). Scale bar, 50 &#x003bc;m.</p></caption><graphic xlink:href="marinedrugs-17-00043-g007"/></fig><table-wrap id="marinedrugs-17-00043-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-17-00043-t001_Table 1</object-id><label>Table 1</label><caption><p>Primers used for the qRT-PCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequence (5&#x02032;-3&#x02032;)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">algD-F</td><td align="center" valign="middle" rowspan="1" colspan="1">AGAAGTCCGAACGCCACA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">algD-R</td><td align="center" valign="middle" rowspan="1" colspan="1">TCCAGCTCGCGGTAGAT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pelA-F</td><td align="center" valign="middle" rowspan="1" colspan="1">CCTTCAGCCATCCGTTCTTCT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pelA-R</td><td align="center" valign="middle" rowspan="1" colspan="1">TCGCGTACGAAGTCGACCTT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pslA-F</td><td align="center" valign="middle" rowspan="1" colspan="1">AAGATCAAGAAACGCGTGGAAT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pslA-R</td><td align="center" valign="middle" rowspan="1" colspan="1">TGTAGAGGTCGAACCACACCG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mexY-F</td><td align="center" valign="middle" rowspan="1" colspan="1">TTACCTCCTCCAGCGGC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mexY-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GTGAGGCGGGCGTTGTG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mexZ-F</td><td align="center" valign="middle" rowspan="1" colspan="1">TTACCTCCTCCAGCGGC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">mexZ-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GTGAGGCGGGCGTTGTG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16S rRNA-F</td><td align="center" valign="middle" rowspan="1" colspan="1">AACCTGGGAACTGCATCCAA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16S rRNA-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTTCGCCACTGGTGTTCCTT</td></tr></tbody></table></table-wrap></floats-group></article>